2025-11-17T08:48:49-08:00 2024-12-31 990 2024-01-01 741541767 Clayton Foundation For Research CLAY 7138175259 One Riverway 1500 Houston TX 77056 Jarred W Sloan President 2025-11-17 true 2024 2025-03-06 01:10:19Z Jarred W Sloan One Riverway 1500 Houston TX 77056 15895618 false X N/A X 1965 TX The primary mission is to conduct medical research in conjunction with hospitals for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind. 5 0 53 0 8075000 2025000 96250 0 2729478 12739333 143062 93000 11043790 14857333 150000 51500 0 6488826 6744599 0 0 4111704 4142103 10750530 10938202 293260 3919131 130572468 144353789 7121038 6584095 123451430 137769694 X The primary mission is to conduct medical research in conjunction with hospitals for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind. The secondary mission is to transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products for the use and benefit of mankind through the Foundation's supporting entities. false false 1030206 A long standing research project at the University of Texas at Austin under the direction of Dr. Brent Iverson is in the field of engineering proteases. One aim of the project is to discover engineered proteases that will serve as more efficient, next generation antibody replacements. The engineered proteases will cleave the protein disease target in a catalytic fashion, thus requiring much less drug and enabling far lower doses and potentially fewer side effects. This project has resulted in the generation of a technology platform to support the development of protease therapeutics called Yeast Endoplasmic Reticulum Sequestration Screening (YESS). In addition to protease engineering, this platform is generating valuable information on enzyme substrate profiling. This allows to profile resistance in kinase inhibitor drugs and to generate kinase inhibitors and protease inhibitors with very low resistance and much higher specificity. This platform has been validated, and lead small drug candidates are currently being developed. Several publications have created interest in the scientific community in the YESS platform. Patent applications have been filed by RDF, one of the Foundation?s supporting entities, on several discoveries arising out of this research. 964510 A research project at Baylor College of Medicine in gene and protein therapy focuses on inappropriate cell division and cell death within the human body. Much of the work is devoted to intraocular angiogenesis, with particular attention to: (1) the signals that control this process, (2) the development of animal models of human ocular disease, and (3) development of potential therapies. New targets have been identified and potential therapeutic agents are being developed and tested for the treatment of wet AMD, Diabetic Retinopathy, and Retinopathy of Prematurity. 910134 The conduct of a longstanding research program at the University of Texas M. D. Anderson Cancer Center(which program moved to Texas A&M Institute of Biosciences and and Technology during the year) , the purpose of which is to design and develop novel targeted therapeutic agents that target a powerful human toxin to specifically destroy cancer cells for the treatment of numerous cancer targets and other disease indications. A number of collaborations have been undertaken with researchers at various institutions (e.g., University of California San Diego). Patent applications have been filed by Research Development Foundation (RDF), a tax exempt supporting organization of the Foundation (see schedule R, Part III), on more than twenty discoveries, and a number of patents have been issued. Licensing efforts have been ongoing and have resulted in several licenses. 825546 Vaccines, Diagnostics and Therapeutics for the Ehrlichioses at The Univerity of Texas Medical Branch at Galveston 807116 Development of Biorepository and Novel Therapeutic Strategies for Hepatocellular Carcinoma at the University of Texas Health Science Center at San Antonio 674935 Early Detection and Treatment of Glaucoma Baylor College of Medicine Houston 637144 Identification of Host-based Antiviral Targets at the University of Texas Southwestern Medical Center Dallas 622259 The Use of Light for Cardiological, Surgical, and Related Purposes at the University of Texas Health Science Center at San Antonio 589586 Antibody Discovery and Optimization Using the Eclonal Technology at The University of Texas at Austin 495150 Electroceutical Sciences and Medicine at Dell Medical School at the University of Texas 491527 Developing Drug Delivery Systems for Testing Solid Tumors at Dell Medical School at the University of Texas 425701 Discovering New Mechanisms and Therapeutics for Brain Injury at the University of Texas Southwestern Medical Center Dallas 361410 Development of Artificial Neurotransmitter Systems at the University of Texas at Austin 236704 Optimization and Charactorization of AAV for Gene Therapy at Dell Medical School at The University of Texas 51500 Grants 6167078 51500 9071928 true true false false false false false false false true true false false true false true false true false false true false false false false false false true false true false false false false false false false true false false false false false true true false false false true 11 0 true 53 true false false false false false false false 0 false false false false false false false X 5 0 true false false false false false false true true false false true true true true true true true true false X Jarred W Sloan 7138165565 One Riverway Suite 1500 Houston TX 770561904 Jarred W Sloan Trustee, President, Treasurer 20.00 20.00 X X 283402 402613 99413 Robert M Wallace Trustee, Vice President 20.00 20.00 X X 210286 475729 99413 Lynn P Carter Trustee 8.00 32.00 X 100624 585391 99413 Joan S Dunlap Trustee VP, Secretary 4.00 36.00 X X 159140 458605 89294 Brian W Crozier Trustee, Chairman 5.00 10.00 X X 100624 256424 49850 Robert L Evans VP, Assistant Treasurer 40.00 0.00 X 222000 0 83150 Kimberly A Shipley Assistant Secretary 40.00 0.00 X 178200 0 76580 Lawrence H Cheung Project Researcher 40.00 0.00 114406 0 40030 1368682 2178762 637143 8 false true false Brorby Crozier & Dobie PC 111 Congress Ave Suite 2250 Austin TX 78701 Legal 578723 1 2025000 2025000 0 2405499 2405499 0 93000 93000 0 11372119 1038285 10333834 10333834 10333834 0 0 0 0 14857333 12832333 51500 51500 0 0 0 1666825 930273 736552 589844 412891 176953 2825950 2669369 156581 334099 309157 24942 1121848 1031710 90138 206033 166775 39258 0 22306 16730 5576 53757 43006 10751 0 0 341081 341081 58742 46390 12352 0 94463 67069 27394 0 0 0 39534 39534 0 0 0 0 398768 283125 115643 239083 207997 31086 Medical research supplies 1545511 1545511 Charge for research lab use 803705 803705 Research equipment 237107 237107 Tuition for researchers 94959 94959 213087 115120 97967 10938202 9071928 1866274 0 1750906 634743 0 0 245846 373726 0 0 0 0 200426 179407 4434562 2289075 2544256 2145487 101051932 102655928 0 0 0 24779102 38364498 130572468 144353789 7121038 6584095 7121038 6584095 X 82886840 97145314 40564590 40624380 123451430 137769694 130572468 144353789 X 3919131 10419434 -20301 X false true X true false X Baylor College of Medicine and Other Hospitals See Part VI Houston TX Part I: Additional Information Part I, Line 4: The Foundation's primary purpose is to directly engage in the continuous active conduct of medical research in conjunction with various nonprofit hospitals. The hospital locations where such research is conducted are The University of Texas M D Anderson Cancer Center (Houston, Texas), The University of Texas Medical Branch (Galveston, Texas), Baylor College of Medicine (Houston, Texas), The University of Texas Southwestern Medical Center (Dallas, Texas), The University of Texas Health Science Center at San Antonio, Dell Medical School at The University of Texas (Austin, Texas) and Texas A&M Institute of Biosciences and Technology(Houston, Texas). Additional research is conducted at the University of Texas Austin under a research affiliation agreement with The University of Texas System ("System") that provides for collaboration with any of the System's component hospital institutions whenever appropriate to further the research. Part I, Line 12f: Supported Org Not Named in Organizing Documents RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39166467 39166467 39166467 39166467 39166467 39166467 39166467 39166467 39166467 39166467 1.00000 false false false 490116 451668 38448 756120 740760 15360 3188326 1096647 2091679 2145487 Charitable Remainder Trusts 1457913 Controlled Corporation 256510 Limited Partnership Investments 36650075 38364498 X 24944563 10419434 16000 10435434 14509129 341081 7123 348204 14857333 10429540 -167581 -167581 10597121 341081 341081 10938202 Part V, Line 4: Intended uses of the endowment fund. The Board of Trustees of the Foundation has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the fair value of the donor contributions as of the contribution dates of the donor-restricted endowment funds. As a result of the interpretation, the Foundation classifies as permanently restricted net assets the original value of the donated contribution to the permanent endowment. Accordingly, only the income, including net realized and unrealized gains, is to be used for the Foundation's activities, except when such assets must be distributed in order to maintain the Foundation's qualification as a medical research organization as defined in the Internal Revenue Code and the regulations thereunder. Part X : FIN48 Footnote From the Federal Income Taxes section of the footnote to the audited financial statements: "The Foundation has no uncertain tax positions". Part XI, Line 2d: Other revenue amounts included in F/S but not included on form 990 Revenue from controlled corporation $16000 Part XI, Line 4b: Other revenue amounts included on 990 but not included in F/S Distribution from controlled corporation $7123 Central America and Caribbean 0 0 Investments N/A 6990510 6990510 6990510 true false true true false false true Georgetown University 37th O Streets NW Washington DC 20057 530196603 501(c)(3) 10000 0 N/A N/A Gen Purpose 0 1 Additional Supplemental Information The Foundation makes these small grants to qualifying public charities after confirming the grantee's exemption. X true true X X X X X false false false false false false false false false Brian W Crozier Trustee, Chairman 100624 256424 49850 150474 256424 Jarred W Sloan Trustee, President, Treasurer 283402 402613 77484 21929 360886 424542 Joan S Dunlap Trustee VP, Secretary 159140 458605 58967 30327 218107 488932 Kimberly A Shipley Assistant Secretary 178200 76580 254780 Lawrence H Cheung Project Researcher 114406 40030 154436 Lynn P Carter Trustee 100624 585391 99413 100624 684804 Robert L Evans VP, Assistant Treasurer 222000 83150 305150 Robert M Wallace Trustee, Vice President 210286 475729 77484 21929 287770 497658 Part I, Line 1a: Relevant information in regards to selections on 1a. Part II, Compensation from Unrelated Organizations Part I Line 1a: Foundation representatives on Foundation business may travel first class under the travel policy approved by the Board, but such persons sometimes fly economy, depending upon routes and convenience of flight schedules. The travel policy does not permit charter travel, and no charter travel was provided to any of such persons. Brorby Crozier Dobie PC See schedule O 589844 Legal Services false Form 990, Part VI, Section B, Line 11b Form 990 is prepared by the Foundation's accounting staff and sent to the Brorby, Crozier & Dobie law firm for review by a tax partner. Each trustee is given a copy of the return for review by the Treasurer prior to filing. Once satisfied with the content of the Form 990, the trustees approve the return for filing with the Internal Revenue Service, and the return is signed and dated by the appropriate officer of the Foundation. Form 990, Part VI, Section B, Line 12c Annually, the trustees and officers review the Conflicts of Interest Policy adopted by the Foundation. At a meeting of the Board each year, both the trustees and the officers sign and date a statement which affirms that such person has received a copy of the conflict of interest policy, has read and understands the policy, has agreed to comply with the policy, and understands that the Foundation is a charitable organization and that in order to maintain its federal tax exemption it must engage primarily in activities which accomplish one of more of its tax-exempt purposes. It is the policy of the Foundation to assure that any conflicts of interest or potential conflicts of interest are fully disclosed to the Board before a decision is made or before the Foundation enters into a proposed transaction. Where necessary to determine whether a conflict of interest exists, after disclosure of the financial interest and all material facts, and after any discussion with the interested person, he or she leaves the Board meeting while the determination of whether a conflict of interest exists is discussed. If the Board determines that a conflict exists, the Board then determines whether the transaction or arrangement is fair and reasonable and should be permitted despite the conflict (or not) as being in the best interests of the Foundation. In instances where the Board has determined that a member has failed to disclose an actual or possible conflict of interest, it will take appropriate disciplinary and/or corrective action. Form 990, Part VI, Section B, Line 15a Several written opinions have been obtained from well recognized independent accounting and consulting firms as to the reasonableness of the compensation being paid to the officers and trustees of the Foundation (including amounts paid by related organizations). In addition, all steps listed in the regulations under IRC Section 4958 (including approval by a compensation committee composed of disinterested persons) have been taken to obtain the rebuttable presumption that compensation paid to the trustees and officers is reasonable. More specifically, the Foundation has periodically engaged an independent consulting firm to review the compensation of the officers and trustees of the Foundation and the group of related and supporting entities. Such consulting firm examines the relevant facts and collects information and data from the Foundation. It also collects and analyzes compensation data from a peer group of unrelated non-profit and for-profit organizations that it selects for comparability purposes. Such firm then renders a written report and opinion containing its conclusions and recommendations. Such report including a thorough description of the facts and the comparability analysis and data is provided to the Foundations Compensation Committee. Such committee, which has the sole authority to approve officer and trustee compensation, constitutes an authorized body composed of persons that do not have a conflict of interest with respect to such compensation arrangements under the rules and requirements set forth in Reg. 53.4958-6(c)(1). The committee meets and reviews the consulting firm's report and the comparability analysis and data. At the meeting, the committee has the opportunity to ask questions and request additional information from a Foundation representative on the committee (who recuses himself from the meeting before any action is taken). After review of the relevant documents and data and after deliberations, the independent committee members make the determination with respect to the amount and reasonableness of the officer and trustee compensation arrangements. Such determination is binding on the trustees and officers of the Foundation. Detailed minutes of each Compensation Committee meeting are contemporaneously prepared and maintained in the Foundations files. Form 990, Part VI, Section B, Line 15b See Line 15 a for the description of the compensation review and approval of other officers or key employees. Form 990, Part VI, Section C, Line 19 No documents available to the public. Form 990, Part XI, Line 9 Postretirement health benefit charge = -$20301 Part 1, Line 4 & Part VI, Line 1b - Independent Voting Members The recommendation regarding independent members of the governing board of a charity is described and discussed in detail in the report entitled "Principles for Good Governance and Ethical Practice, A Guide for Charities and Foundations", Reference Edition, that was published in October 2007 by the Panel on the Nonprofit Sector. This panel was convened by Independent Sector and its recommendations have been cited with approval by the Internal Revenue Service. Such report concludes that the principle with respect to independent directors does not apply to various types of organizations, including medical research organizations described in IRC 170(b)(1)(A)(iii), such as the Foundation. In this regard, Footnote 27 on page 23 expressly states as follows:" This principle [a substantial majority of the Board should be independent]does not apply to private foundations; medical research institutions...; supporting organizations or subsidiaries that are required by law to include representatives of the supported organizations or sponsoring charities on their board..." [footnote listing continues with several other specific types of Section 501(c)(3) organizations]. Part VI, Section A, Line 2 and Schedule L, Part I Each of the trustees and officers of the Foundation also serve as trustees, directors and/or officers of the various related organizations listed in Schedule R. Mr. Brian W. Crozier, who became a trustee of the Foundation on January 1, 2019, and was elected Chairman in April 2023, has provided legal services to the Foundation since 1985. Mr. Crozier is a member of the law firm of Brorby, Crozier & Dobie, P.C. (B,C&D) owning more than 35 of B,C&D. Such firm is engaged to furnish legal services to the Foundation on an hourly basis in connection with various matters upon the request of Foundation trustees and officers other than Mr. Crozier. The Foundation's relationship with B,C&D pre-dates the naming of Mr. Crozier as a trustee. In his capacity as a member of the Board of the Foundation, Mr. Crozier has not participated in any decisions involving assignment of work to B,C&D and have not been involved in the review and approval of the detailed monthly invoices sent by B,C&D to the Foundation. In his capacity with B,C&D, Mr. Crozier did not participate in the preparation of the monthly statements of amounts billed to the Foundation. The other trustees (with Mr. Crozier abstaining) approved this arrangement with full knowledge of Mr. Crozier's position as a member of and a holder of a financial interest in B,C&D. Several written opinions have been obtained from well recognized independent accounting and consulting firms as to the reasonableness of the legal fees being paid to B,C&D by the Foundation. In addition, all steps listed in the regulations under IRC Section 4958 (including approval by a compensation committee composed of disinterested persons) have been taken to obtain the rebuttable presumption that compensation paid to B,C&D is reasonable. More specifically, the Foundation has periodically engaged an independent consulting firm to review the legal fees paid to B,C&D. Such consulting firm examines the relevant facts and collects information and data from the Foundation and B,C&D. It also collects and analyzes compensation data from a peer group of comparable unrelated attorneys and law firms that it selects for comparability purposes. Such consulting firm then renders a written report and opinion containing its conclusions and recommendations. Such report (including a thorough description of the facts and the comparability analysis and data) is provided to the Foundations Compensation Committee. Such committee, which has the sole authority to approve the compensation arrangement with B,C&D (including hourly rates), constitutes an authorized body composed of persons that do not have a conflict of interest with respect to such compensation arrangements under the rules and requirements set forth in Reg. 53.4958-6(c)(1). The committee meets and reviews the consulting firms report and the comparability analysis and data. At the meeting, the committee has the opportunity to ask questions and request additional information from a Foundation representative on the committee (who recuses himself from the meeting before any action is taken). After review of the relevant documents and data and after deliberations, the independent committee members make the determination with respect to the amount and reasonableness of the compensation arrangement. Such determination is binding on B,C&D. Detailed minutes of each Compensation Committee meeting are contemporaneously prepared and maintained in the Foundations files. Clayton Foundation Company One Riverway Suite 1500 Houston TX 77056 746035675 Title Holding Corporation TX 501(c)(2) N/A Clayton Foundation for Research true Foundation for Research 402 N Division Street Carson City NV 89703 880234196 Medical research NV 501(c)(3) Line 12 Type 2 NA false Clayton Medical Research Foundation Inc 402 North Division St Carson City NV 89703 510306704 Medical Research DE 501(c)(3) Line 12 Type 2 NA false Research Development Foundation 402 North Division St Carson City NV 89703 880234325 Technology Transfer NV 501(c)(3) Line 12 Type 2 NA false Institut Clayton de la Recherche Case Postale 284 Geneva SZ 1211 Medical research SZ Exempt Swiss Charity Line 12, Type 2 (if N/A false Foundation Services Inc 402 North Division St Carson City NV 89703 880374369 Holding Company NV NA C false Clayton Biotechnologies Inc One Riverway Suite 1520 Houston TX 77056 760377287 Technology Transfer NV Found Services Inc C true Julie Davis Clayton Trust One Riverway Suite 1500 Houston TX 77056 746085161 Charitable Remainder Trust TX Clayton Foundation T false false false true false false false false false false false false false false false false false true false false Part V, Line 2 - Transactions With Related Parties Per instructions, none of the transactions are reportable on Line 2.